DC hospital treating Rep. Scalise has ‘extremely low’ safety ratings

House Minority Whip Steve Scalise, R-Louisiana, has been treated at MedStar Washington Hospital Center since he was shot in June. The hospital has a less-than-stellar safety reputation, according to USA Today.

The CMS Hospital Compare site gives it a two stars out of five rating, labeling it as “worse than the national rate” on complications like catheter-associated urinary tract infections (CAUTI) in the intensive care unit. The Leapfrog Group gave the hospital a “D” in its last hospital safety grades report.

At Washington Hospital Center, “infections are a pattern and a serious one,” said Leapfrog Group CEO Leah Binder. “They are significantly below the national average in four out of five areas that we have data, which suggests an inability to prevent infections.”

Scalise has undergone several surgeries since he was admitted, as the bullet damaged bone, blood vessels and internal organs. After being upgraded to fair condition, he was moved back to the ICU last week for another surgery and was back in serious condition.

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.